Latest Medtech News
From a $455M deal to advance a next-generation heart pump to AI-powered cath lab robotics and invasive brain-computer interfaces, funding is targeting some of the most complex areas of medical technology. Capital is also supporting the scale-up of cementless implants, robotic rehabilitation and next-generation drug delivery systems.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like these. Subscribe to our Industry Insights for weekly coverage.
Boston Scientific and Blackstone Life Sciences co-fund VITALYST in $455M deal
Boston Scientific and Blackstone Life Sciences agreed to a $455M co-funding deal to advance VITALYST, a next-generation microaxial pump designed to provide circulatory support for patients with cardiogenic shock. The funding will support continued development of the temporary heart pump.
Boston Scientific Chairman and CEO Mike Mahoney
Laza Medical secures up to $160M to bring AI and Robotics to the cath lab
Laza Medical secured up to $160M in a Series B led by GE HealthCare, with participation from returning investors, to advance its AI-powered robotic imaging technology for cardiovascular interventions. The system remains in development and has not received regulatory clearance or approval.
Founder and Board Chairman Amr Salahieh: "The cath lab is poised for a fundamental evolution, and intelligent imaging powered by AI will play a defining role in what comes next."
Active Technology raises RMB 464M to advance invasive brain-computer interfaces
Shanghai-based Active Technology raised RMB 464M ($69.3M) in an Angel+ round co-led by Gaorong Ventures, SSCILF and Shanghai Science & Technology Investment, bringing its total angel-stage funding to around RMB 800M ($119M). The funding will support R&D, clinical translation and industrialisation of its invasive brain-computer interface platforms for motor, visual and affective applications.
Enjosim Medical raises RMB 200M to expand drug delivery manufacturing
Enjosim Medical secured RMB 200M ($29.9M) in a Series B led by CICC Capital, with participation from CoStone Capital, Qiming Venture Partners and other investors. The funding will expand global production capacity, advance next-generation self-administration devices and support overseas regulatory approvals and market expansion.
OSSTEC raises $8M for first U.S. cases of ASCENT cementless partial knee
OSSTEC closed an $8M round led by EMBRYO Ventures, with participation from Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance and Empirical Ventures. The funding will support FDA clearance and first-in-human U.S. procedures for its ASCENT cementless partial knee system, planned for H1 2027, while advancing its pipeline of 3D-printed cementless implants.
CEO Maxwell Munford: "This financing moves our focus from preparation to patients,"
Flow Medical raises $6M with strategic investors for PE thrombolysis system
Flow Medical raised $6M from new and returning investors, including two unnamed strategic medical device companies. The funding will support first-in-human evaluation of its investigational HELYX-PE catheter system, further development and manufacturing, and preparation for a U.S. pivotal study.
Co-Founder and CEO Jennifer Fried: "The vast majority of patients who are eligible for catheter-based intervention actually don’t receive it."
BionicM raises JPY 710M in Series B to prepare for U.S. launch
BionicM raised 710M Yen ($4.4M) in the first close of its Series B, led by B Dash Ventures and Mitsubishi UFJ Capital, bringing total funding from equity and grants to ¥2.58 billion. The investment will strengthen manufacturing and U.S. commercial operations ahead of the planned 2027 launch of ASISTA, its powered prosthetic knee designed to assist both flexion and extension.
President and CEO Sun Xiaojun: "We are extremely encouraged to have reached our Series B 1st Closing, thanks to the support of strong investors both domestically and internationally."
Bioliberty raises $3.3M in Series A extension to expand rehabilitation platform
Bioliberty closed a $3.3M Series A extension, bringing total funding across its pre-Series A, Series A and extension to $13.5M. New investors included TGH Ventures, Ballad Ventures, Whiterock and 25m Health. The funding will support expansion of its rehabilitation technology into home settings, connected recovery data across care environments and further AI capabilities for therapy and patient assessment.
CEO Rowan Armstrong: "This investment allows us to significantly expand our capabilities, from advancing how we measure patient recovery using computer vision and AI-driven assessments, to extending our product into patients’ homes."
1nhaler raises £2.2M to advance cardboard inhaler towards approval
1nhaler secured £2.2M ($2.9M) in follow-on funding led by Archangels, with support from Scottish Enterprise and BBB Investments. The funding will advance its single-dose cardboard dry powder inhaler, 1nhaler Salbutamol, through manufacturing transfer and clinical testing ahead of a planned regulatory filing in late 2027.
Co-Founder and CEO Lisa McMyn: "This investment takes us to one of the most important milestones in our journey - taking our own lead product into the clinic."
BioMetal Health secures $1M at UCLA Draper Innovation Showcase
BioMetal Health received $1M at the 2026 UCLA Draper Innovation Showcase, the largest investment awarded among five startups sharing $2.1M. The company also won a $2,500 Audience Award, bringing its total recognition at the event to $1.0025M.
CEO Jerry Yen
